GIOTRIF (Boehringer Ingelheim Pty Ltd)
Product name
GIOTRIF
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
179 working days (255)
Active ingredients
afatinib
Registration type
EOI
Indication
GIOTRIF (film coated tablets) is now also indicated as monotherapy for the treatment of patients with locally advanced or metastatic squamous non-small cell carcinoma of the lung progressing on or after platinum-based chemotherapy.